ArticleNAR genomics and bioinformatics2026
DNA augmentations for semi-supervised learning in genomic sequence classification.
Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Semi-supervised learning (SSL) is a natural fit for genomics, where unlabeled sequences are abundant but high-quality labels are scarce due to costly curation. However, most SSL pipelines rely on generic perturbations that are not tailored to biological constraints, and it remains unclear which augmentation designs yield reliable gains for DNA sequence classification. In this application note, we present an empirical study of genome-aware weak-strong augmentation recipes for pseudo-label-based SSL, focusing on FixMatch and FlexMatch with a GROVER DNA language model backbone. Across two classification benchmarks-antimicrobial resistance (AMR) drug-class prediction from AMR gene sequences and multi-class oncovirus family classification from simulated 150 bp tumor-like reads-we systematically evaluate 25 weak/strong augmentation pairs constructed from biologically motivated operators, including reverse-complement, codon-level back-translation, mild masking/substitution (NN), high-rate substitution, and length-preserving insertion-deletion (indel). We find consistent trends: (i) moderate, sequence-preserving perturbations yield the best accuracy-stability trade-off, (ii) excessive masking or aggressive mutation increases variance and degrades performance, and (iii) short-segment masking (NN) for weak augmentation followed by an indel rate (around 5%) for strong augmentation emerge as a robust strategy to learn from unlabeled genomic data. We release implementations and recommended defaults to facilitate reproducible SSL for genomic sequence modeling under limited-label regimes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.